Leading Researcher: Fibrosis Improved in Systemic Sclerosis and IPF Models With Monoclonal Antibody

Author: Margarida Azevedor
Date Published: February-2016
Source: Scleroderma News

Researchers at ChemomAb and Meir Medical Center in Tel Aviv, Israel, and the University of Florence, Italy, recently presented a study investigating the therapeutic effect of the monoclonal antibody CM-101 in animal models of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). The data was presented last week in a talk titled “CM-101, a Novel Monoclonal Antibody Blocking CCL24 Ameliorates Experimental Systemic Sclerosis (SSc) and Idiopathic Pulmonary Fibrosis (IPF)” at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal. Systemic sclerosis and IPF are two conditions that involve the development and accumulation of fibrotic tissue and progressive decline of the patient’s health status.